Vasundhara Rasayans Ltd
VRLBSE
₹133.00▼ -3.05 (-2.24%)
Whole company worth₹43 Cr
Price for ₹1 of profit₹7.3
1-year range₹100 – ₹220
The short version
A slow-growing, profitable business — priced low for what it earns.
What Vasundhara Rasayans does
Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids
Worked out from Vasundhara Rasayans's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Vasundhara Rasayans is a micro-sized company in pharmaceuticals.
Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids
- Whole company is worth
- ₹43 crore
- Run by
- RAJESH POKERNA
- Shareholders
- 5,909 people
- Listed since
- 2014
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have grown 10% a year for 5 years.
At that pace a business doubles in size roughly every 8 years. Profit grew even faster, at 15% a year — the business is keeping more of each rupee it brings in.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
Out of every ₹100 it sells, it keeps ₹16 as profit.
Here is where the money from Vasundhara Rasayans's sales went in FY26, the latest full year it has reported.
₹42
₹33
₹16
- ₹42Making or buying what it sellsraw materials, stock, goods bought for resale
- ₹33Running the businessstaff, rent, marketing, power and everything else
- ₹1.1Interest on its loansthe cost of borrowed money
- ₹1.2Wear and tearmachines, stores and buildings losing value over time
- ₹5.8Taxincome tax paid to the government
- ₹16Profit it keepswhat is left for the company's owners
On the money its owners have put in
It earns ₹14 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹14
₹0₹10₹20₹30₹40
That figure is called return on equity (ROE). Between ₹12 and ₹20 is a respectable return. For comparison, a bank fixed deposit pays roughly ₹6–7.
Does the profit turn into cash?
For every ₹100 of profit it reported, ₹-9 actually came in as cash.
Profit it reported₹16 Cr
Cash its business brought in−₹1.4 Cr
Over the last 3 years: ₹16 crore of profit but only −₹1.4 crore of cash. A wide gap like this is worth understanding before trusting the profit figure.
04Is the price high or low?
You pay ₹7.3 for every ₹1 of profit it makes in a year.
This is the P/E ratio: share price divided by a year's profit per share. A P/E of 7.3 means buyers are paying for about 7.3 years of today's profit up front.
The share price over the past year
It is 40% below its highest price of the past year and 33% above its lowest.
05Who owns it?
Its founders and parent group own 62 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 5,909 people and institutions hold its shares.
As filed for the quarter ending 30 Sept 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
One thing going well, two things worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Thinly traded — only about ₹2 lakh of shares change hands a day, so buying or selling can move the price.
- The share price is 40% below its high of the past year.
07What happened lately?
Latest quarter: sales down 8%, profit up 14%.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹6.9 Cr
▼ 8.3% on a year earlier
Profit
₹0.7 Cr
▲ 14.0% on a year earlier
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Vasundhara Rasayans?
This page describes Vasundhara Rasayans using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Vasundhara Rasayans Ltd (VRL): company summary
The company's annual revenue rose 5.1% to ₹36 crore, while net profit surged 36.2% to ₹6 crore.
Vasundhara Rasayans Ltd (VRL) is a micro-cap Healthcare company valued at ₹43 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Vasundhara Rasayans Ltd last traded at ₹133, down 2.24% on the day.
- Financial performance
- The company's annual revenue rose 5.1% to ₹36 crore, while net profit surged 36.2% to ₹6 crore. However, the latest quarter saw revenue fall 8.3% year-on-year to ₹7 crore, despite a 14.0% increase in net profit to ₹1 crore.
- Valuation multiples
- The stock trades at 7.3 times earnings, a discount to the Healthcare median of 32.0, 1.13 times book value. It yields 1.4%.
- Things to watch
- The stock is 36.5% below its 52-week high, and the latest quarter's revenue decline contrasts with the annual profit growth. The company's revenue has declined in the last quarter, which could signal short-term challenges.
- Where it stands
- The company's net profit margin improved by 3.7 percentage points to 16.2%, and return on equity remained at 14.2%. The stock is 36.5% below its 52-week high, but the latest quarter's revenue decline highlights a recent challenge.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals
Explore Vasundhara Rasayans Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Vasundhara Rasayans Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LZYDUS LIFESCIENCES LTDAPOLLO HOSPITALS ENTER. LLAURUS LABS LIMITEDCIPLA LTDDR. REDDY S LABORATORIESMANKIND PHARMA LIMITEDAUROBINDO PHARMA LTDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Vasundhara Rasayans Ltd with peers
Vasundhara Rasayans Ltd vs SUN PHARMACEUTICAL IND LVasundhara Rasayans Ltd vs DIVI S LABORATORIES LTDVasundhara Rasayans Ltd vs TORRENT PHARMACEUTICALS LVasundhara Rasayans Ltd vs ZYDUS LIFESCIENCES LTDVasundhara Rasayans Ltd vs APOLLO HOSPITALS ENTER. LVasundhara Rasayans Ltd vs LAURUS LABS LIMITED
Related tools & concepts
Value Vasundhara Rasayans Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing